Brooks Lab.

Which are the latest news on Brooks Lab.?

How big is Brooks Lab.?

As of 10th June, Brooks Laboratories Ltd has a market capitalization of 208.00 Cr, with recent net sales of 85.74 Cr and a net profit of 24.58 Cr. Shareholder's funds are 98.10 Cr, and total assets are valued at 123.69 Cr.

As of 10th June, Brooks Laboratories Ltd has a market capitalization of 208.00 Cr, categorizing it as a Micro Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 85.74 Cr and a Net Profit of 24.58 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 98.10 Cr and Total Assets valued at 123.69 Cr.

Who are in the management team of Brooks Lab.?

The management team of Brooks Lab consists of Rajnish Kumar Bedi, Deepak Mahajan, and Sonia Gupta as Independent Directors, and Kaushalya Singh and Jitendra Pratap Singh as Whole Time Directors.

The management team of Brooks Lab includes the following members:<BR><BR>1. **Rajnish Kumar Bedi** - Independent Director<BR>2. **Deepak Mahajan** - Independent Director<BR>3. **Sonia Gupta** - Independent Director<BR>4. **Kaushalya Singh** - Whole Time Director<BR>5. **Jitendra Pratap Singh** - Whole Time Director<BR><BR>If you need more details about their roles or responsibilities, feel free to ask!

Why is Brooks Laboratories Ltd falling/rising?

As of 10-Jun, Brooks Laboratories Ltd's stock price is Rs 67.24, down 1.48%. Despite recent short-term gains, the stock has struggled over the long term, with a year-to-date decline of 16.21% and a 48.26% drop over the past year, compounded by decreasing investor participation.

As of 10-Jun, Brooks Laboratories Ltd's stock price is currently at Rs 67.24, reflecting a decrease of Rs 1.01 or 1.48%. Despite this decline, the stock has shown some positive momentum in recent days, having gained 4.78% over the last two days and outperforming its sector by 2.29% today. The stock opened with a significant gain of 3.96% and reached an intraday high of Rs 70.95. However, it also experienced a low of Rs 66, indicating volatility within the trading session.<BR><BR>In terms of longer-term performance, the stock has had a mixed trajectory. Over the past week, it has increased by 4.25%, while over the past month, it has surged by 32.10%. However, year-to-date, the stock is down 16.21%, and over the past year, it has fallen by 48.26%. This suggests that while there are short-term gains, the stock has struggled significantly over longer periods.<BR><BR>Additionally, there are signs of declining investor participation, with delivery volume falling by 29.58% compared to the five-day average. This decrease in trading activity could contribute to the stock's current price decline. The stock's moving averages indicate that it is performing better than its shorter-term averages but is still below its 200-day moving average, which may reflect a longer-term bearish trend.<BR><BR>Overall, while Brooks Laboratories Ltd has shown some recent gains, the current price drop can be attributed to volatility, declining investor interest, and a challenging longer-term performance outlook.

What does Brooks Lab. do?

Brooks Laboratories Ltd is a micro-cap pharmaceutical manufacturing company focused on producing injectables, tablets, and dry syrups for domestic markets. As of March 2026, it reported net sales of 20 Cr and a net profit of 2 Cr, with a market cap of INR 208 Cr.

Overview: <BR>Brooks Laboratories Ltd is a pharmaceutical manufacturing company operating in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap.<BR><BR>History: <BR>The company was incorporated on January 23, 2002, and has been focused on manufacturing injectables, tablets, and dry syrups for domestic customers. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 20 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: 2 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 208 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 8.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.01 <BR>Return on Equity: 20.04% <BR>Price to Book: 1.64 <BR><BR>Contact Details: <BR>Address: Village Kishanpura, Nilagarh Road Baddi Solan Himachal Pradesh : 174101 <BR>Tel: 91-1795-654001/02/03 <BR>Email: investors@brookslabs.net <BR>Website: http://www.brookslabs.net

Should I buy, sell or hold Brooks Laboratories Ltd?

Are Brooks Laboratories Ltd latest results good or bad?

Brooks Laboratories Ltd's latest results are concerning, showing a 31.08% decline in net profit and a 29.34% drop in net sales, marking their weakest performance in eight quarters. The significant decline in operating margin and misleading profit after tax margin indicate serious operational challenges that investors should monitor closely.

The latest results for Brooks Laboratories Ltd are concerning and indicate significant operational challenges. In the quarter ending December 2025, the company reported a consolidated net profit of ₹5.50 crore, which represents a decline of 31.08% compared to the previous quarter. Additionally, net sales dropped sharply by 29.34% quarter-on-quarter to ₹16.57 crore, marking the weakest performance in eight quarters. <BR><BR>The operating margin also suffered, falling to 4.41%, the lowest level recorded in recent history, down from 10.75% in the previous quarter. This decline in profitability raises red flags about the company's operational efficiency and ability to sustain its business model.<BR><BR>Furthermore, the reported profit after tax margin of 33.19% is misleading as it was significantly influenced by tax adjustments rather than genuine operational performance. The underlying operational deterioration suggests that the company is facing serious challenges in maintaining its revenue and profitability.<BR><BR>Overall, the results can be characterized as bad, reflecting a troubling trend that investors should closely monitor.

When is the next results date for Brooks Laboratories Ltd?

The next results date for Brooks Laboratories Ltd is 06 February 2026.

The next results date for Brooks Laboratories Ltd is scheduled for 06 February 2026.

How has been the historical performance of Brooks Lab.?

Brooks Lab's historical performance shows a recovery in net sales from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, alongside improved operating profit of 4.94 Cr, despite a consolidated net loss of -9.97 Cr in Mar'25. Total assets increased to 123.69 Cr, and cash flow from operations turned positive at 2.00 Cr, indicating a potential turnaround.

Answer:<BR>The historical performance of Brooks Lab shows a fluctuating trend in key financial metrics over the past five years.<BR><BR>Breakdown:<BR>Brooks Lab's net sales increased from 63.20 Cr in Mar'23 to 82.56 Cr in Mar'25, indicating a recovery from a dip in Mar'22 when sales were at 91.08 Cr. Total operating income followed a similar trend, rising to 82.56 Cr in Mar'25 from a low of 63.20 Cr in Mar'23. However, total expenditure decreased from 105.44 Cr in Mar'22 to 77.62 Cr in Mar'25, contributing to an operating profit of 4.94 Cr in Mar'25, a significant improvement from a loss of 26.42 Cr in Mar'23. Despite this, the company reported a consolidated net profit of -9.97 Cr in Mar'25, although this was an improvement from -19.59 Cr in Mar'24. The earnings per share also showed a trend of improvement, moving from -8.46 in Mar'23 to -3.38 in Mar'25. On the balance sheet, total assets increased to 123.69 Cr in Mar'25 from 90.45 Cr in Mar'24, while total liabilities also rose to 123.69 Cr in Mar'25, reflecting a stable financial position. Cash flow from operating activities turned positive at 2.00 Cr in Mar'25, contrasting with negative cash flows in previous years, indicating a potential turnaround in operational efficiency.

Is Brooks Lab. overvalued or undervalued?

As of October 20, 2025, Brooks Lab. is considered overvalued with a high PE ratio of 173.77 and an EV to EBITDA of 46.27, alongside poor financial performance and a year-to-date stock decline of 35.25%, making it an unfavorable investment at its current price of 119.75.

As of 20 October 2025, the valuation grade for Brooks Lab. has moved from very expensive to expensive, indicating a slight improvement in its perceived value. However, the company remains overvalued based on key financial metrics. The PE ratio stands at an exceptionally high 173.77, while the EV to EBITDA ratio is 46.27, both of which are significantly higher than its peers. In contrast, Sun Pharma has a PE ratio of 35.32 and an EV to EBITDA of 23.96, while Cipla, considered attractive, has a PE of 24.56 and an EV to EBITDA of 17.35.<BR><BR>Overall, Brooks Lab. appears to be overvalued given its high valuation ratios and poor financial performance, including a negative ROE of -10.15% and a low ROCE of 3.18%. Recent stock performance has also been disappointing, with a year-to-date decline of 35.25%, compared to a 7.97% increase in the Sensex, further reinforcing the notion that the stock is not a favorable investment at its current price of 119.75.

Who are the top shareholders of the Brooks Lab.?

The top shareholders of Brooks Lab include Atul Ranchal with 19.24%, Quant Mutual Fund at 9.9%, and individual investors collectively holding 31.86%. Foreign institutional investors hold a minimal 0.05%.

The top shareholders of Brooks Lab include the promoters, with Atul Ranchal holding the highest individual stake at 19.24%. Additionally, Quant Mutual Fund, specifically through the Quant Business Cycle Fund, is the highest public shareholder with a holding of 9.9%. The company also has mutual funds holding 9.9% through one scheme and foreign institutional investors (FIIs) holding a minimal 0.05%. Individual investors collectively own 31.86% of the company.

Has Brooks Lab. declared dividend?

No Dividend History Available

Who are the peers of the Brooks Lab.?

Brooks Lab.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Everest Organics, SMS Lifesciences, Zenotech Lab., and Fredun Pharma. Brooks Lab. has below average management risk and growth, with a 1-year return of 83.44%, lower than Everest Organics' 252.60% but higher than Fredun Pharma's -8.48%.

Peers: The peers of Brooks Lab. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Everest Organics, SMS Lifesciences, Zenotech Lab., and Fredun Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and the rest. Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Average management risk is noted at Everest Organics, SMS Lifesciences, Zenotech Lab., Fredun Pharma, and the rest. Below Average management risk is attributed to Brooks Lab. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, while below average growth is seen at Divi's Lab., Torrent Pharma, Brooks Lab., Everest Organics, SMS Lifesciences, Zenotech Lab., and the rest. Average growth is noted at SMS Lifesciences, and good growth is observed at Fredun Pharma. Capital structure is excellent at Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, while good capital structure is found at Torrent Pharma, average at SMS Lifesciences, and below average at Brooks Lab., Everest Organics, and Fredun Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Everest Organics at 252.60%, while the lowest is Fredun Pharma at -8.48%. Brooks Lab.'s 1-year return of 83.44% is significantly higher than Fredun Pharma's but lower than Everest Organics'. Additionally, peers with negative six-month returns include Cipla, Torrent Pharma, and Fredun Pharma.